Merck’s ophthalmology effort tied to its $1.3 billion upfront acquisition of EyeBio has hit a pivotal milestone, according to the company’s first reported success. The development suggests the acquired platform is beginning to generate clinical signal after years of execution and portfolio buildout beyond Keytruda. The update matters for investors tracking Big Pharma’s risk calculus in specialty eye disease, where development timelines and endpoint selection can quickly determine whether external bets translate into differentiated products. Overall, Merck’s progress provides a datapoint for how late-stage validation can emerge from platform-centric licensing and acquisitions in ophthalmology.